Keywords: UK, NICE, Novartis, Tasigna, Bristol-Myers Squibb, Sprycel, Myeloid leukemia

UK patient group makes case for CML drugs Sprycel and Tasigna given initial “thumbs down” by the NICE

Article | 24 February 2010

Print This

Following the latest draft guidance from the UK’s National Institute for Health and Clinical Excellence (NICE) on drugs for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in